MedTrace Logo

a Vigibase Pharmacovigilance Study of ENzalutamide Drug-induced neurotoxicitY

NCT04290611 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 500000

Last updated 2023-04-13

No results posted yet for this study

Summary

Enzalutamide may lead to various adverse reactions. This study investigates reports of different neurological toxicities in the World Health Organization's (WHO) global database of individual safety case reports (VigiBase).

Conditions

Interventions

DRUG

Enzalutamide

Enzalutamide for the treatment of prostate cancer or other solid tumors

Sponsors & Collaborators

  • Groupe Hospitalier Pitie-Salpetriere

    lead OTHER

Eligibility

Min Age
18 Years
Max Age
100 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-01-01
Primary Completion
2023-01-01
Completion
2023-04-08
FDA Drug
Yes

Countries

  • France

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04290611 on ClinicalTrials.gov